QuidelOrtho [QDEL] vs Abbott Laboratories [ABT] Detailed Stock Comparison
QuidelOrtho
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: QuidelOrtho wins in 8 metrics, Abbott Laboratories wins in 10 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | QuidelOrtho | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -0.91 | 16.64 | QuidelOrtho |
| Price-to-Book Ratio | 0.63 | 4.56 | QuidelOrtho |
| Debt-to-Equity Ratio | 100.33 | 26.50 | Abbott Laboratories |
| PEG Ratio | -0.01 | 0.45 | QuidelOrtho |
| EV/EBITDA | 7.58 | 20.71 | QuidelOrtho |
| Profit Margin (TTM) | -17.01% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -0.73% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -15.64% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 1.36% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-112.10M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -38.01% | 17.66% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 0.64 | 5.35 | QuidelOrtho |
| Enterprise Value | $4.39B | $237.22B | Abbott Laboratories |
| EV/Revenue Ratio | 1.60 | 5.50 | QuidelOrtho |
| Gross Profit Margin (TTM) | 44.78% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $41 | $25 | QuidelOrtho |
| Earnings per Share (Diluted) | $-6.84 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | -0.03 | 0.71 | QuidelOrtho |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
QuidelOrtho vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| QuidelOrtho | 8.73% | 7.60% | 9.24% | -7.55% | -33.51% | -38.06% |
| Abbott Laboratories | 0.45% | 0.64% | 5.46% | 0.83% | -1.75% | 16.88% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| QuidelOrtho | -38.01% | -66.00% | -82.88% | 36.43% | 129.63% | 226.70% |
| Abbott Laboratories | 17.66% | 30.12% | 19.68% | 188.11% | 454.54% | 517.85% |
Performance & Financial Health Analysis: QuidelOrtho vs Abbott Laboratories
| Metric | QDEL | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.77B | $230.77B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 911,915 | 5,640,670 |
| 90 Day Avg. Volume | 1,383,058 | 7,136,830 |
| Last Close | $27.90 | $132.59 |
| 52 Week Range | $22.05 - $49.45 | $110.86 - $141.23 |
| % from 52W High | -43.58% | -6.12% |
| All-Time High | $306.72 (Aug 03, 2020) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -90.90% | -7.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.04% | 0.07% |
| Quarterly Earnings Growth | -0.04% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.17% | 0.32% |
| Operating Margin (TTM) | -0.01% | 0.20% |
| Return on Equity (TTM) | -0.16% | 0.31% |
| Debt to Equity (MRQ) | 100.33 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $41.25 | $29.05 |
| Cash per Share (MRQ) | $2.25 | $4.18 |
| Operating Cash Flow (TTM) | $200.40M | $9.04B |
| Levered Free Cash Flow (TTM) | $410.48M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: QuidelOrtho vs Abbott Laboratories
| Metric | QDEL | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -0.91 | 16.64 |
| Forward P/E | 9.81 | 25.70 |
| PEG Ratio | -0.01 | 0.45 |
| Price to Sales (TTM) | 0.64 | 5.35 |
| Price to Book (MRQ) | 0.63 | 4.56 |
| Market Capitalization | ||
| Market Capitalization | $1.77B | $230.77B |
| Enterprise Value | $4.39B | $237.22B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.60 | 5.50 |
| Enterprise to EBITDA | 7.58 | 20.71 |
| Risk & Other Metrics | ||
| Beta | -0.03 | 0.71 |
| Book Value per Share (MRQ) | $41.25 | $29.05 |
Financial Statements Comparison: QuidelOrtho vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | QDEL | ABT |
|---|---|---|
| Revenue/Sales | $692.80M | $10.36B |
| Cost of Goods Sold | $349.50M | $4.47B |
| Gross Profit | $343.30M | $5.89B |
| Research & Development | $53.20M | $716.00M |
| Operating Income (EBIT) | $48.70M | $1.69B |
| EBITDA | $154.20M | $2.66B |
| Pre-Tax Income | $-8.80M | $1.78B |
| Income Tax | $3.90M | $453.00M |
| Net Income (Profit) | $-12.70M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | QDEL | ABT |
|---|---|---|
| Cash & Equivalents | $127.10M | $6.53B |
| Total Current Assets | $1.26B | $23.15B |
| Total Current Liabilities | $1.05B | $13.00B |
| Long-Term Debt | $2.27B | $12.74B |
| Total Shareholders Equity | $3.00B | $49.06B |
| Retained Earnings | $123.10M | $47.72B |
| Property, Plant & Equipment | $2.35B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | QDEL | ABT |
|---|---|---|
| Operating Cash Flow | $41.90M | $1.42B |
| Capital Expenditures | $-56.20M | $-484.00M |
| Free Cash Flow | $9.40M | $933.00M |
| Debt Repayment | $-36.00M | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | QDEL | ABT |
|---|---|---|
| Shares Short | 6.59M | 18.33M |
| Short Ratio | 4.67 | 2.44 |
| Short % of Float | 0.16% | 0.01% |
| Average Daily Volume (10 Day) | 911,915 | 5,640,670 |
| Average Daily Volume (90 Day) | 1,383,058 | 7,136,830 |
| Shares Outstanding | 67.26M | 1.73B |
| Float Shares | 62.65M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.18% | 0.81% |
Dividend Analysis & Yield Comparison: QuidelOrtho vs Abbott Laboratories
| Metric | QDEL | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |